دورية أكاديمية
أعرض في EDS

The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia.

التفاصيل البيبلوغرافية
العنوان: The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia.
المؤلفون: Kamaeva DA; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia., Kazantseva DV; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia., Boiko AS; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia., Mednova IA; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia., Smirnova LP; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia., Kornetova EG; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia., Ivanova SA; Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya Str. 4, Tomsk 634014, Russia.; Department of Psychiatry, Addictology and Psychotherapy, Siberian State Medical University, Moskovsky Trakt, 2, Tomsk 634050, Russia.
المصدر: Biomedicines [Biomedicines] 2023 Apr 14; Vol. 11 (4). Date of Electronic Publication: 2023 Apr 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: Catalytic antibodies, or abzymes, are capable of not only binding but also hydrolyzing various proteins. Previously, an increase in the level of myelin basic protein (MBP)-hydrolyzing activity of antibodies was shown in patients with a number of neurological and mental disorders, including schizophrenia. Furthermore, antipsychotic therapy is known to induce a change in cytokine levels in patients with schizophrenia, which affects regulation of the immune response and inflammatory status. This study investigated the influence of typical and atypical antipsychotics on catalytic antibody activity and the 10 major pro- and anti-inflammatory serum cytokine levels. The study included 40 patients with schizophrenia: 15 treated with first-generation antipsychotics and 25 treated with atypical antipsychotics for 6 weeks. It was found that treatment with atypical antipsychotics changed the levels of some pro-inflammatory cytokines. Antipsychotic therapy also caused a significant decrease in MBP-hydrolyzing activity in patients with schizophrenia ( p = 0.0002), and associations of catalytic activity with interleukins were observed.
References: Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(8):61-4. (PMID: 18833110)
Transl Psychiatry. 2021 Jun 30;11(1):365. (PMID: 34226491)
Brain Res Bull. 2001 Jul 15;55(5):597-610. (PMID: 11576756)
Open Biol. 2015 Sep;5(9):150064. (PMID: 26382278)
Psychiatry (Edgmont). 2007 Jul;4(7):28-37. (PMID: 20526405)
Oxid Med Cell Longev. 2021 Jan 23;2021:8881770. (PMID: 33552387)
Neurosci Biobehav Rev. 2017 Jun;77:122-128. (PMID: 28285148)
Eur J Immunol. 2010 Jul;40(7):1830-5. (PMID: 20583029)
Annu Rev Med. 2013;64:393-406. (PMID: 23020880)
Mol Psychiatry. 2001 Jan;6(1):79-82. (PMID: 11244489)
Indian J Psychiatry. 2008 Jul;50(3):171-6. (PMID: 19742187)
Cytokine. 2021 May;141:155441. (PMID: 33529887)
Sci Immunol. 2018 Jul 6;3(25):. (PMID: 29980618)
World J Psychiatry. 2021 Jul 19;11(7):316-324. (PMID: 34327124)
Pharmaceuticals (Basel). 2021 May 09;14(5):. (PMID: 34065135)
BMC Psychiatry. 2021 Nov 11;21(1):561. (PMID: 34763685)
Front Psychiatry. 2021 May 07;12:655178. (PMID: 34025476)
Front Neurosci. 2015 Oct 21;9:372. (PMID: 26539073)
Immune Netw. 2017 Oct;17(5):276-286. (PMID: 29093649)
Int J Neuropsychopharmacol. 2014 Oct 31;18(4):. (PMID: 25522386)
Infect Immun. 2017 Aug 18;85(9):. (PMID: 28674034)
Front Psychiatry. 2022 Apr 25;13:880568. (PMID: 35546942)
Front Psychiatry. 2021 Mar 05;12:536257. (PMID: 33746786)
Curr Pharm Des. 2005;11(8):973-84. (PMID: 15777248)
Medicine (Baltimore). 2020 Apr;99(15):e19694. (PMID: 32282724)
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18336-41. (PMID: 22025707)
FEBS Lett. 2006 Sep 18;580(21):5089-95. (PMID: 16950261)
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295. (PMID: 25190079)
Patol Fiziol Eksp Ter. 2015 Jul-Sep;(3):81-8. (PMID: 26852601)
Transl Psychiatry. 2017 Feb 7;7(2):e1024. (PMID: 28170004)
J Cell Mol Med. 2007 May-Jun;11(3):531-51. (PMID: 17635644)
Int J Mol Sci. 2022 Oct 11;23(20):. (PMID: 36292926)
Physiol Behav. 2014 Apr 22;129:194-8. (PMID: 24576679)
Mol Psychiatry. 2022 Jun;27(6):2787-2802. (PMID: 35365810)
Front Psychiatry. 2020 Aug 05;11:775. (PMID: 32848941)
Int J Mol Sci. 2020 Sep 30;21(19):. (PMID: 33008051)
Int J Neuropsychopharmacol. 2013 Apr;16(3):691-700. (PMID: 23164411)
Focus (Am Psychiatr Publ). 2020 Oct;18(4):391-401. (PMID: 33343251)
J Autoimmun. 2006 Sep;27(2):71-80. (PMID: 16997531)
Curr Top Behav Neurosci. 2020;44:227-244. (PMID: 30993585)
Focus (Am Psychiatr Publ). 2021 Jan;19(1):3-13. (PMID: 34483761)
Front Med (Lausanne). 2021 Nov 24;8:757655. (PMID: 34901070)
Schizophr Res. 2009 Apr;109(1-3):159-66. (PMID: 19272755)
Curr Top Behav Neurosci. 2020;44:49-66. (PMID: 31115797)
Schizophr Res. 2020 Dec;226:13-23. (PMID: 32089474)
Vojnosanit Pregl. 2017 Apr;73(4):312-7. (PMID: 29308860)
World Psychiatry. 2020 Feb;19(1):15-33. (PMID: 31922684)
J Cell Mol Med. 2018 Dec;22(12):5816-5832. (PMID: 30265424)
Int J Mol Sci. 2021 Mar 08;22(5):. (PMID: 33800290)
J Psychiatr Res. 2002 Sep-Oct;36(5):331-6. (PMID: 12127601)
Immunity. 2008 May;28(5):687-97. (PMID: 18468463)
Mol Immunol. 1999 Dec;36(18):1215-22. (PMID: 10684961)
Front Psychiatry. 2020 Nov 09;11:607590. (PMID: 33240137)
J Mol Recognit. 2019 Feb;32(2):e2759. (PMID: 30112774)
Neuropsychobiology. 2004;49(4):205-9. (PMID: 15154399)
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(6):59-66. (PMID: 34283531)
Int J Dev Neurosci. 2018 Oct;69:1-9. (PMID: 29902518)
NPJ Schizophr. 2021 Feb 26;7(1):13. (PMID: 33637732)
Biochemistry (Mosc). 2018 May;83(5):507-526. (PMID: 29738685)
Biochemistry (Mosc). 2003 Oct;68(10):1081-8. (PMID: 14616078)
Psychopharmacology (Berl). 2016 May;233(9):1575-89. (PMID: 26268146)
Yonsei Med J. 2019 Feb;60(2):126-131. (PMID: 30666833)
J Neuroimmunol. 2015 Oct 15;287:1-8. (PMID: 26439953)
Zh Nevropatol Psikhiatr Im S S Korsakova. 1989;89(7):56-9. (PMID: 2800814)
Front Psychiatry. 2019 Dec 06;10:892. (PMID: 31908647)
J Immunol. 2016 May 15;196(10):4075-81. (PMID: 27067006)
Brain Sci. 2022 Aug 30;12(9):. (PMID: 36138890)
J Immunol Res. 2020 Aug 10;2020:8986521. (PMID: 32851101)
East Asian Arch Psychiatry. 2013 Mar;23(1):21-8. (PMID: 23535629)
معلومات مُعتمدة: 21-75-00071 Russian Science Foundation
فهرسة مساهمة: Keywords: abzymes; antibodies; biomarker; catalytic IgG; cytokine; humoral immunity; myelin; myelin basic protein; schizophrenia
تواريخ الأحداث: Date Created: 20230516 Latest Revision: 20230519
رمز التحديث: 20230519
مُعرف محوري في PubMed: PMC10136109
DOI: 10.3390/biomedicines11041179
PMID: 37189796
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines11041179